Biosimilars

Biosimilar Structural Comparison of Commercially Sourced Reference Standards by MMS Rapidly Detects Subtle but Critical Differences to Correctly Predict Activity for Use in an ELISA Product

It was determined that many of the Bovine Serum Albumin (BSA) reference candidates did not exhibit acceptable activity after inclusion into the final product though all purchased samples shared the same name and identification. The inconsistency in activity causes delays, increases cost of manufacture, and adds an element of variability. Current in-house biophysical techniques fail to correctly identify the inactive candidates prior to product inclusion due to inconclusive results or a lack of sensitivity. Thus a more accurate, reliable analytical…

Accelerating Biosimilar Development Programs using Contract Testing and Manufacturing Organizations

A rapid increase in the number of companies working on the development and registration of biosimilars and the need to get these products to market with speed has lead biosimilar developers to turn to contract research organizations (CROs) when they lack either the internal capability or capacity for conducting certain work. Throughout the biosimilar development pathway, a product sponsor can choose to conduct the work itself or use service contractors. Contractors can be niche providers of a single aspect of…

Contract Test Services from Associates of Cape Cod, Inc.: Specializing in Testing for Endotoxin and Glucan Contamination

Associates of Cape Cod,® Inc. Contract Test Service (CTS) laboratory specializes in testing for endotoxin and glucan contamination and has notable experience in endotoxin testing. CTS performs all methods of the BET assay: gel-clot, chromogenic, and turbidimetric. CTS is GMP compliant and ISO registered. We’re licensed by the DEA as a laboratory capable of handling all controlled drug substances except those included in Schedule I. Endotoxin testing can be performed in accordance with FDA, USP, EP and/or JP, depending on…

Platform Purification of Six Biosimilar Molecules Using Amsphere A3 – Protein A Resin

Currently more than 70 biosimilar mAbs (monoclonal antibodies) are under development and multiple originator mAbs are going off-patent in the next 3-4 years. Protein A resin remains the most important workhorse for the purification of monoclonal antibodies. Protein A resin has a high impact on both development and manufacturing cost, in particular during early stage clinical phases. This application note summarizes the key performance parameters for our high capacity protein A resin, Amsphere A3, for 6 biosimilar molecules of which…

Exploring Protein Stability by nanoDSF

nanoDSF determines thermal and chemical protein stability with ultra-high resolution and with unmatched reproducibility. The detection of the intrinsic tryptophan fluorescence enables measurements at close-to-native conditions in any buffer, even in the presence of detergents. nanoDSF is applied in antibody engineering, membrane protein research, formulation and quality control.

Are You Into Biosimilars?

Learn about GE Healthcare Life Sciences’ aim to help bioprocessing teams map out the optimal plan to transform a biosimilars project idea into result, with greater flexibility and confidence and with reduced time and cost.

Polishing of Monoclonal Antibodies Using Captoâ„¢ MMC ImpRes in Bind and Elute Mode

GE Healthcare Life Sciences MAb purification toolbox employs protein A chromatography media (resins) such as MabSelect SuReâ„¢ or MabSelect SuRe LX, in the capture step. After the initial protein A step, there is a range of options for intermediate and polishing purification steps. One option is Capto MMC ImpRes, a new chromatographic medium based on a multimodal cation exchange ligand. This work describes a rapid procedure to establish a robust second step in bind/elute mode for the purification of a…